Your session is about to expire
← Back to Search
Cabozantinib + Nivolumab + Ipilimumab for Soft Tissue Sarcoma
Study Summary
This trial is testing whether adding PD-1 and CTLA-4 inhibitors to cabozantinib will improve the response rate in patients with soft tissue sarcoma, and whether cabozantinib priming will increase the response to nivolumab and ipilimumab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 45 Patients • NCT02101736Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of lung scarring or inflammation not caused by infections.I am currently being treated for an infection.I haven't had cancer treatment in the last 4 weeks.You have tumors that can be measured and are at least 10mm in size on CT scan or 20mm on chest x-ray, or can be measured using calipers during a clinical exam.Your platelet count is at least 100,000 per cubic millimeter of blood without any transfusion.I have had a solid organ or bone marrow transplant.You have other medical conditions that could make it unsafe for you to participate in the study.I have a serious illness that is not under control.My condition worsened after 1-2 treatments.I have had cancer before, but it fits the exceptions.My sarcoma is caused by a genetic change, but it's not ASPS.I haven't had radiation for bone metastasis in the last 2 weeks or any other radiation in the last 4 weeks.I have cancer that has spread to my brain.My cancer has not improved after 1-2 treatments, but it's been over a year since my initial therapy.You are currently pregnant or breastfeeding.I have been treated with cabozantinib or drugs targeting PD-1, PD-L1, or CTLA-4.I haven't taken any kinase inhibitor medication in the last 2 weeks.I haven't taken steroids or immunosuppressants in the last 14 days.I require dialysis.I have not had major surgery in the last 2 weeks.I have not received a live vaccine in the last 30 days.Your hemoglobin level must be at least 9.0 grams per deciliter.I have an autoimmune disease.My sarcoma cannot be surgically removed and has spread.I cannot swallow pills.I am 18 years old or older.My blood tests and organ functions are normal.My cancer can be biopsied to test for PD-L1 if there's no old tissue sample.I have recovered from side effects of previous treatments.I agree to use birth control during the study.I am 18 years old or older.You need to have a minimum of 2,000 white blood cells per cubic millimeter of blood.You are currently taking any experimental drugs as part of another study.I am currently taking blood thinners.My white blood cell count is healthy without needing medication to boost it.I am fully active and can carry on all my pre-disease activities without restriction.My sarcoma is confirmed by tests and cannot be surgically removed or has spread.I have a condition that prevents my body from absorbing nutrients properly.Your bilirubin levels must be within certain limits, unless you have a condition called Gilbert's disease.
- Group 1: Crossover from Cohort A to Cohort B: Cabozantinib + Nivolumab + Ipilimumab
- Group 2: Cohort A: Cabozantinib
- Group 3: Cohort B: Cabozantinib + Nivolumab + Ipilimumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we currently able to sign people up for this clinical trial?
"That is right, the clinical trial is ongoing and currently recruiting patients. It was first posted on January 5th, 2021 with the most recent update being March 8th, 2022. The study wants to enroll 105 patients from 4 different locations."
Are there any negative side effects associated with Cabozantinib?
"This is a Phase 2 trial, so cabozantinib's safety is only supported by preliminary data."
At how many research facilities is this investigation being conducted?
"Multiple locations are recruiting patients for this clinical trial, such as Stanford University Medical Center in Stanford, the University of Colorado in Aurora, Abramson Cancer Center at Pennsylvania Hospital in Philadelphia, and 4 other centres."
Are there any ongoing or previous clinical trials that have studied Cabozantinib?
"In total, there are 879 active clinical trials studying the efficacy of Cabozantinib. Out of these medical studies, 96 are in Phase 3. Additionally, while many of the tests for this medication are being conducted out of Pittsburgh, Pennsylvania, there are 46889 locations running these sorts of trials."
What are the common indications for Cabozantinib?
"Cabozantinib is commonly used to treat unresectable melanoma. Cabozantinib can also be effective at treating other cancers such as squamous cell carcinoma, high risk of recurrence, and disease."
Share this study with friends
Copy Link
Messenger